Showing results (171-180 of 187) with videos related to

Sort By:
Pageof 19
Nature Communications|January 19, 2023
Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trialYouyi Fong, Yunda Huang, David Benkeser, et al.
The New England Journal of Medicine|December 15, 2021
Efficacy and Safety of NVX-CoV2373 in Adults in the United States and MexicoLisa M Dunkle, Karen L Kotloff, Cynthia L Gay, et al.
European Heart Journal. Cardiovascular Imaging|June 15, 2020
Non-obstructive high-risk plaques increase the risk of future culprit lesions comparable to obstructive plaques without high-risk features: the ICONIC studyRichard A Ferraro, Alexander R van Rosendael, Yao Lu, et al.
JACC. Cardiovascular Imaging|December 17, 2018
Selective Referral Using CCTA Versus Direct Referral for Individuals Referred to Invasive Coronary Angiography for Suspected CAD: A Randomized, Controlled, Open-Label TrialHyuk-Jae Chang, Fay Y Lin, Dan Gebow, et al.
Journal of Cardiovascular Computed Tomography|June 20, 2022
Age related compositional plaque burden by CT in patients with future ACSAlexander R van Rosendael, Inge J van den Hoogen, Fay Y Lin, et al.
Human Vaccines & Immunotherapeutics|December 12, 2024
Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-M<sup>TM</sup> adjuvant (NVX-CoV2373) versus a primary series in people living with and without HIV-1 infection in South Africa: A randomized crossover phase 2a/2b trialVivek Shinde, Anthonet Lombard Koen, Zaheer Hoosain, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 25, 2025
Analysis of antibody markers as immune correlates of risk of severe COVID-19 in the PREVENT-19 efficacy trial of the NVX-CoV2373 recombinant protein vaccineYouyi Fong, Yunda Huang, Ying Huang, et al.
The New England Journal of Medicine|June 30, 2021
Safety and Efficacy of NVX-CoV2373 Covid-19 VaccinePaul T Heath, Eva P Galiza, David N Baxter, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 9, 2022
Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled TrialPaul T Heath, Eva P Galiza, David Neil Baxter, et al.
The Lancet. HIV|April 30, 2022
Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trialShabir A Madhi, Dhayendre Moodley, Sherika Hanley, et al.
Pageof 19